Loading stock data…
Lakefront Biotherapeutics (LKFT)
$29.67+0.19 (+0.64%)
Market ClosedLast close Jun 29
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lakefront Biotherapeutics NV in the Healthcare sector is trading at $29.67 with a market capitalization of $1.9B. Wall Street consensus targets $22.92 (2 analysts), implying a -22.8% move over the next 12 months. The stock is currently 21% below its 52-week high of $37.78, remaining 5.5% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. Risk note: RSI 73 is overbought against a weak tape. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply -22.8% downside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 73 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.48M↓ | $900.82M↑ | $71.16M↑ | $65.29M↓ | $74.98M |
| Gross Profit | $1.68M↓ | $900.37M↑ | $60.31M↓ | $60.58M↓ | $61.25M |
| Operating Income | -$63.70M↓ | $758.80M↑ | -$41.67M↑ | -$57.03M↑ | -$158.71M |
| Net Income | $14.49M↓ | $782.15M↑ | -$202.11M↓ | -$105.75M↑ | -$153.40M |
Peer Comparison
JNJUNHPFE
Fundamentals
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.86B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
3.31
Beta
Defensive asset. Lower volatility than the S&P 500.
0.13
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
15.02%
Volume
Today's trading volume
121,987
Recent News
Lakefront Biotherapeutics (ENXTAM:LKFT) Stock After Recent Gains Still A Recovery Opportunity?
Investors may be wondering whether Lakefront Biotherapeutics at €24.94 is starting to look like value, or if the risks still outweigh the potential upside. The stock has risen 2.2% over the past week and 6.6% over the last month, although it remains down 11.4% year to date and has fallen 1.7% over the past year. Recent coverage has focused on Lakefront Biotherapeutics as a smaller biotech stock that has seen substantial 3 year and 5 year share price declines, which can draw interest from...
Gilead Sciences (GILD), Lakefront Biotherapeutics Acquire Ouro Medicines to Advance Autoimmune Pipeline
Gilead Sciences Inc. (NASDAQ:GILD) is one of the best quality growth stocks to buy. On June 4, Gilead Sciences and Lakefront Biotherapeutics completed the acquisition of Ouro Medicines, a strategic move designed to bolster their inflammation and immunology pipelines. The centerpiece of this acquisition is gamgertamig (OM336), a clinical-stage T cell engager being developed as […]
Lakefront Biotherapeutics NV (AMS:LKFT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Lakefront Biotherapeutics NV ( AMS:LKFT ) last week reported its latest quarterly results, which makes it a good time...